Payment overview · 2025
General Payments
$1,001.84
33 reported records · 16 companies
Healthcare provider profile · identity verified
David I Levenson, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Endocrinology, Diabetes & Metabolism · BOCA RATON, FL · NPI 1194808063
Verified facts
What the public records show
CMS Open Payments records show David I Levenson, M.D. received $1,001.84 in general payments during 2025 across 33 reported records.
Medicure Pharma Inc. accounted for 19.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 18 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Korlym, Mounjaro.
Corcept Therapeutics reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Korlym as an associated drug or biological on 56316 records involving 19205 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Korlym by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 200 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 268 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 164 claims for Trulicity by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SOLIQUA 100/33 as an associated drug or biological on 43 records involving 15 distinct recipient NPIs. Public Medicare Part D data also shows 67 claims for Soliqua 100-33 by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medicure Pharma Inc. | Unresolved — no canonical attribution shown | $195.19 | 19.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $125.00 | 12.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $118.08 | 11.8% | 6 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $95.64 | 9.6% | 4 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $76.26 | 7.6% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $67.14 | 6.7% | 3 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $60.98 | 6.1% | 3 | 2025 |
| Neurocrine BioSciences, Inc. | Unresolved — no canonical attribution shown | $50.19 | 5.0% | 2 | 2025 |
| Mannkind Corporation | Unresolved — no canonical attribution shown | $37.38 | 3.7% | 2 | 2025 |
| Sequel Med Tech, LLC | Unresolved — no canonical attribution shown | $30.47 | 3.0% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $30.29 | 3.0% | 1 | 2025 |
| Madrigal Pharmaceuticals | Unresolved — no canonical attribution shown | $24.85 | 2.5% | 1 | 2025 |
| ViiV Healthcare Company | Unresolved — no canonical attribution shown | $23.49 | 2.3% | 1 | 2025 |
| Esperion Therapeutics, Inc. | Unresolved — no canonical attribution shown | $22.80 | 2.3% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $22.57 | 2.2% | 1 | 2025 |
| Insulet Corporation | Unresolved — no canonical attribution shown | $21.51 | 2.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $977.80 | 32 |
| Education | $24.04 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Zypitamag Normalized: zypitamag |
Drug | Medicure Pharma Inc. | $195.19 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $95.64 | 4 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $76.26 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $67.14 | 3 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $62.67 | 3 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $62.67 | 3 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $60.98 | 3 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $55.41 | 3 | 2025 |
Source payment records
|
|||||
| CRENESSITY Normalized: crenessity |
Drug | Neurocrine BioSciences, Inc. | $50.19 | 2 | 2025 |
Source payment records
|
|||||
| AFREZZA Normalized: afrezza |
Drug | Mannkind Corporation | $37.38 | 2 | 2025 |
Source payment records
|
|||||
| TWIIST Normalized: twiist |
Device | Sequel Med Tech, LLC | $30.47 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $30.29 | 1 | 2025 |
Source payment records
|
|||||
| REZDIFFRA Normalized: rezdiffra |
Drug | Madrigal Pharmaceuticals | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| DOVATO Normalized: dovato |
Drug | ViiV Healthcare Company | $23.49 | 1 | 2025 |
Source payment records
|
|||||
| NEXLETOL Normalized: nexletol |
Drug | Esperion Therapeutics, Inc. | $22.80 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $22.57 | 1 | 2025 |
Source payment records
|
|||||
| Omnipod Normalized: omnipod |
Device | Insulet Corporation | $21.51 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Korlym korlym |
2025 | Korlym | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 268 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Corcept Therapeutics Exact reporting entity; no affiliate inference |
2025 | Korlym open payments reported associated product |
CMS Open Payments — General Payments 56316 supporting records · 19205 recipient NPIs · example record 1214133822 |
Korlym · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
200 | 63 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
268 | 56 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
164 | 26 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | SOLIQUA 100/33 open payments reported associated product |
CMS Open Payments — General Payments 43 supporting records · 15 recipient NPIs · example record 1233224976 |
Soliqua 100-33 · 2024 Exact normalized brand match · 1 Part D row |
67 | 16 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1627 | 434 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 624 | 203 |
| Synthroid | Levothyroxine Sodium | 563 | 137 |
| Metformin Hcl Er | Metformin Hcl | 528 | 166 |
| Atorvastatin Calcium | Atorvastatin Calcium | 512 | 164 |
| Ozempic | Semaglutide | 352 | 82 |
| Metformin Hcl | Metformin Hcl | 289 | 90 |
| Nateglinide | Nateglinide | 272 | 96 |
| Mounjaro | Tirzepatide | 268 | 56 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 258 | 92 |
| Ezetimibe | Ezetimibe | 208 | 72 |
| Jardiance | Empagliflozin | 200 | 63 |
| Losartan Potassium | Losartan Potassium | 198 | 58 |
| Alendronate Sodium | Alendronate Sodium | 179 | 62 |
| Trulicity | Dulaglutide | 164 | 26 |
| Vascepa | Icosapent Ethyl | 141 | 36 |
| Januvia | Sitagliptin Phosphate | 136 | 33 |
| Repaglinide | Repaglinide | 118 | 35 |
| Glimepiride | Glimepiride | 116 | 35 |
| Tresiba Flextouch U-100 | Insulin Degludec | 116 | 47 |
| Lisinopril | Lisinopril | 112 | 34 |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 110 | 38 |
| Simvastatin | Simvastatin | 107 | 35 |
| Dexamethasone | Dexamethasone | 99 | 56 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 99 | 34 |
| Humalog Kwikpen U-100 | Insulin Lispro | 95 | 34 |
| Amlodipine Besylate | Amlodipine Besylate | 93 | 29 |
| Humalog Mix 75-25 Kwikpen | Insulin Lispro Protamin/Lispro | 89 | 30 |
| Novolog Flexpen | Insulin Aspart | 86 | 38 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 25 |
| Potassium Chloride | Potassium Chloride | 75 | 24 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 67 | 16 |
| Methimazole | Methimazole | 63 | 20 |
| Icosapent Ethyl | Icosapent Ethyl | 59 | 23 |
| Calcitriol | Calcitriol | 55 | 17 |
| Raloxifene Hcl | Raloxifene Hcl | 50 | 17 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 47 | 22 |
| Hydrocortisone | Hydrocortisone | 47 | 12 |
| Hydrochlorothiazide | Hydrochlorothiazide | 44 | 15 |
| Tradjenta | Linagliptin | 44 | 13 |
| Risedronate Sodium | Risedronate Sodium | 43 | 17 |
| Ramipril | Ramipril | 40 | 13 |
| Farxiga | Dapagliflozin Propanediol | 39 | 15 |
| Liothyronine Sodium | Liothyronine Sodium | 38 | 11 |
| Ulticare Pen Needle | Pen Needle, Diabetic | 38 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | 15 |
| Rybelsus | Semaglutide | 35 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 34 | 19 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 32 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 31 | suppressed |
| Levemir Flexpen | Insulin Detemir | 30 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 30 | 12 |
| Armour Thyroid | Thyroid,pork | 28 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 13 |
| Famotidine | Famotidine | 23 | 11 |
| Spironolactone | Spironolactone | 23 | suppressed |
| Livalo | Pitavastatin Calcium | 22 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Humalog | Insulin Lispro | 21 | suppressed |
| Testosterone | Testosterone | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | 11 |
| Novolin 70-30 Flexpen | Insulin Nph Hum/Reg Insulin Hm | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 19 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 18 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 17 | suppressed |
| Carvedilol | Carvedilol | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 15 | suppressed |
| Omeprazole | Omeprazole | 15 | suppressed |
| Desmopressin Acetate | Desmopressin Acetate | 14 | suppressed |
| Insulin Lispro Protamine Mix | Insulin Lispro Protamin/Lispro | 14 | suppressed |
| Novolog | Insulin Aspart | 14 | suppressed |
| Omnipod 5 Dexg7g6 Pods (Gen 5) | Insulin Pump Cart,auto,bt,g6/7 | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Victoza 3-Pak | Liraglutide | 14 | suppressed |
| Fenofibrate | Fenofibrate | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Korlym | Mifepristone | 13 | suppressed |
| Unithroid | Levothyroxine Sodium | 13 | suppressed |
| Insulin Aspart Prot Mix 70-30 | Insulin Aspart Prot/Insuln Asp | 12 | suppressed |
| Praluent Pen | Alirocumab | 12 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Genotropin | Somatropin | 11 | suppressed |
| Humulin N Kwikpen | Insulin Nph Human Isophane | 11 | suppressed |
| Humulin R U-500 | Insulin Regular, Human | 11 | suppressed |
| Novolin N Flexpen | Insulin Nph Human Isophane | 11 | suppressed |
| Prednisone | Prednisone | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,001.84 · 33 records | Medicure Pharma Inc. | AFREZZA, CRENESSITY, DOVATO, Dexcom G6 Transmitter, EVENITY, ISTURISA, Kerendia, Korlym, MOUNJARO, NEXLETOL, Omnipod, PROLIA, REZDIFFRA, TEPEZZA, TWIIST, TZIELD, ZEPBOUND, Zypitamag | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Korlym play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Corcept Therapeutics?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error